The NCRI AML19 v2 trial randomised patients generally aged 18-60y with newly diagnosed AML without known adverse karyotype to receive DA 3+10 (Daunorubicin 60mg/m2 on days 1, 3 & 5 plus AraC 100mg/m2 bd on days1-10) plus either a single dose of GO (3mg/m2 on day 1, DAGO1) or two doses (3mg/m2, capped at 5mg on days1 and 4, DAGO2). Patients with a FLT3-ITD or TKD could enter the “Midotarg” pilot and receive 50mg bd of Midostaurin (m) for 14 days following completion of chemotherapy...Overall response (CR + CRi) was achieved in 82% (DAGO1m) and 91% (DAGO2m). Median follow-up is 15months. Estimated OS at 18 months was 82% (Figure 1) and was 81% and 84% for DAGO1m and DAGO2m respectively.